Prospective Cohort With Incident Stroke

Study Overview
=================
Brief Summary
-----------------
The primary aim of the study is to derive and validate risk scores for vascular endpoints (recurrent stroke, myocardial infarction, and other complications of stroke) and for death following an incident stroke. For this purpose patients with an incident stroke will be followed for 36 months with additional assessments at 3, 12, 24 and 36 months.

Detailed Description
-----------------
Risk of vascular disease including stroke, myocardial infarction, and vascular death is high after stroke but there are only few prognostic models for long term risk up to 3 years. About 850 patients with an incident stroke will be followed for 3 years with assessments at baseline and at 3, 12, 24, and 36 months. Factors that have already been reported to be significant predictors of vascular diseases in previous studies as well as new biomarkers (e.g. neuroimaging, blood based biomarkers) identified in this cohort will be considered. The improvement of discrimination including these new variables in the models will be investigated. Several measures of improving predictive properties (e.g. calibration, discrimination, net reclassification) will be used to compare predictive models with different complexity. The model will be validated using the bootstrap method (internal validation) and an independent external sample in cooperation with the prospective CSB-stroke cohort.

Official Title
-----------------
Prospective Cohort With Incident Stroke

Conditions
-----------------
Ischemic Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Language: German First ever acute ischemic stroke that occurred with stroke onset in the last 7 days Written informed consent by patient prior to study participation Willingness to participate in follow-up Exclusion Criteria: Prior stroke (definition according to WHO criteria) Patients presenting brain tumour or brain metastasis Participation in an intervention- / AMG-study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| First ever acute ischemic stroke<br>Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Combined vascular endpoint composed of stroke, myocardial infarction, and vascular death | This evaluation will be based on a structured interview with the patient. In case of positive screening more information will be obtained by hospital or physician. | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Combined vascular endpoint composed of stroke, myocardial infarction, and vascular death | This evaluation will be based on a structured interview with the patient. In case of positive screening more information will be obtained by hospital or physician. In case of death of the patient, evaluation will be based on data from the registry office. | 24 months | 
| Combined vascular endpoint composed of stroke, myocardial infarction, and vascular death | This evaluation will be based on a structured interview with the patient. In case of positive screening more information will be obtained by the physician. In case of death of the patient, evaluation will be based on data from the registry office. | 12 months | 
| Course of cognitive function | This evaluation will be based on a structured interview with the patient. In case of positive screening more information will be obtained by the physician. | 36 months | 
| Course of depression | This evaluation will be based on a structured interview with the patient. In case of positive screening more information will be obtained by the physician. | 36 months |